1. Pharmacokinetic-based criteria for supporting alternative dosing regimens of programmed cell death receptor-1 (PD-1) or programmed cell death-ligand 1 (PD-L1) blocking antibodies for treatment of patients with cancer: guidance for industry Publication: Silver Spring, MD : Center for Drug Evaluation and Research, December 2022 Subject(s): Government RegulationImmune Checkpoint Inhibitors -- administration & dosageImmune Checkpoint Inhibitors -- pharmacokineticsProgrammed Cell Death 1 Receptor -- administration & dosageUnited StatesUnited States. Food and Drug Administration
